ArticleVox sanguinis2026
Evaluating compliance with restrictive blood transfusion practices: A 5-year study from a Greek tertiary hospital.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesOur aim was to retrospectively assess the adherence to a restrictive transfusion strategy (in the context of patient blood management [PBM]) among patients in a Greek tertiary hospital over a 5-year period (2020-2024) following the initial evaluation of the electronic transfusion request system. MATERIALS AND
methodsAnalyses included assessment of time trends-overall and by hospital clinic-in haemoglobin (Hb) levels at transfusion, as well as in the proportion of inappropriate transfusions, based on pre-specified audit criteria (Hb thresholds for red blood cell transfusions).
resultsA total of 23,322 transfusion episodes were recorded among medical patients, with annual counts ranging from 4078 to 5394 and an overall mean transfusion Hb level of 7.18 ± 0.78 g/dL. The proportion of transfusions with Hb levels above 7.00 g/dL decreased significantly from 69.14% in 2020 to 58.83% in 2023 (Cochran-Armitage test for trend, p < 0.01). Among patients without comorbidities (threshold: 7.00 g/dL), 53.34% of transfusions occurred above this cut-off, with an initial drop from 60.41% in 2020 to 47.72% in 2021, followed by a rebound to 58.43% in 2024 (p = 0.25). Transfusions above 8.00 g/dL also declined significantly, from 8.33% in 2020 to 5.20% in 2023 (p < 0.01). Differences were also observed among clinics.
conclusionOverall, moderate compliance with the restrictive transfusion strategy was observed. The initial decline in transfusions above prespecified Hb thresholds followed by fluctuations in subsequent years highlights the need for a consistent, multifaceted effort to optimize blood usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.